TODAY: Join HAYA’s CEO Samir Ounzain , at 18:00 CEST at the 38th Annual meeting of the #ISHR-ES, Session 4. He will be presenting on "RNA-based Therapies for #CardiacFibrosis” Learn more at: ishr2024.sciencesconf.org/resource/page/…

Emely Möller, HAYA’s Project Lead in TME/CAF, had an excellent experience at the #EMBOWorkshop “The Many Faces of Cancer Evolution.” Thank you, EMBO and the organizers, for hosting such a fantastic workshop!

#TOMORROW: Don’t miss the final day of the #CIGSymposium2024:"Novelties in the RNA World." HAYA's CEO, Samir Ounzain , will be presenting on “Unlocking the #RegulatoryGenome: Pioneering RNA-Guided Therapeutics for Cell-State Modulation in Disease Pathogenesis,” at 15:00 CEST. Université de Lausanne

Last Friday, HAYA had the honor of attending the Swiss Economic Forum. Although we didn't take home the top prize in our category, we received tremendous support and encouragement. Congratulations to all the winners of #SEF2024! #lifesciences #biotech #regulatorygenome #lncRNA

HAYA co-founders, CEO Samir Ounzain (Samir Ounzain) and CTO Daniel Blessing, were honored with the inaugural Andreas & Thomas Struengmann Award on Friday night. The award recognizes DACH-region life science entrepreneurs developing revolutionary technologies. hayatx.com/news-and-publi…

Happy #5thBirthday, HAYA! What started as a small #lncRNA biotech has grown into a leader in RNA-based #PrecisionMedicine with a groundbreaking platform for reprogramming disease driving cell-states & the🌍's largest #RegulatoryGenome atlas.Cheers to more years of innovation!🥂

ICYMI: HAYA's been named one of 18 biotechs based in Switzerland to watch by at Labiotech.eu! 🚀 We’re thrilled to be recognized among such innovative peers! Cheers to the Swiss biotech industry and all its groundbreaking companies. shorturl.at/kl4W6 #biotech #innovation

Today, HAYA welcomes former Global Head@Roche, Eric Adam, as #COO. We are thrilled to start working with him to help us #StreamlineOperations and support the development of #StrategicPartnerships and #BusinessIdeas. Welcome to the team, Eric! Learn more: rb.gy/p9v3nk

We’re #Hiring! 🚀 We are looking for passionate, creative, and driven individuals to join #HAYATherapeutics team. OPEN positions #Biomarkers_Lead 🧪 #IT_Manager 💻 Ready to make a real impact? Apply TODAY!👉hayatx.com/careers#sectio…

This month began with #WorldRNADay, but at #HAYA, every day is RNA day! 🌍🧬 RNA isn't just a messenger from our DNA—it's a key player in evolution, cell biology, and a game-changer in therapeutics. 🚀 Learn more: nature.com/articles/d4158…

Ever wondered how quickly #lncRNAs can shape gene expression? ⏰ 🧬 Today, groundbreaking study from John Rinn's laboratory reveals that the lncRNA Firre influences epigenetic and transcriptional states much more rapidly than previously thought. ➡️nature.com/articles/s4146…

📆Will you be attending the SAE Media Group 4th annual #OligonucleotideTherapeuticsDelivery conference? #HAYA’s Dir. of Comp. Biology & Data Science, Marco Mina, will be speaking on "The #DarkGenome as the Next Revolution in #DrugDiscovery”. Learn more at:shorturl.at/O87xx

✈️ Heading to San Diego for the #RNALeadersUSACongress2024? Don't miss, HAYA CEO,Samir Ounzain talk on “Leveraging Proprietary Technology to Identify Novel #lncRNA Therapeutic Targets within the #DarkGenome” on Wednesday, September 4, at 11:45 am.🧬 ➡️shorturl.at/foOKy

Curious to know whether #HAYATherapeutics will be named one of the #TOP100SSU 2024 🏆🇨🇭? Register NOW and join the #LiveStream of the award ceremony this Wednesday at 6pm CET to find out! 📍Registration (LinkedIn account required): shorturl.at/xhxMK Venturelab

🚀 We are thrilled to announce a multi-year #collaboration with Eli Lilly and Company to discover novel #RegulatoryGenome targets for #Obesity & related #MetabolicConditions. Learn more: hayatx.com/news-and-publi…

𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐍𝐞𝐰𝐬: The Co-Founder and CEO of HAYA Therapeutics describes the "dark genome" approach that led to a deal today with Eli Lilly for obesity and metabolic disease. Full video: biotechtv.com//post/haya-the…

Under a multi-year agreement announced Wednesday, Eli Lilly and Company will leverage Haya Therapeutics’ proprietary RNA-guided genome platform to identify drug targets to address the chronic conditions. #pharma #biospace hubs.li/Q02NCywl0

Eli Lilly is pairing up with a so-called “dark genome” biotech startup to hunt for a new generation of obesity and metabolic drugs. endpts.com/lilly-inks-obe…

🏆 We're excited to announce that #HAYA has been named TOP100 Swiss Startups' 5th Best Startup in 🇨🇭, and 1st in the Biotech & Drug Discovery sectors! A wonderful recognition of our team's commitment to our mission! #TOP100SSU Venturelab

✈️ Will you be attending the Hypertrophic Cardiomyopathy Medical Society #2024ScientificSessions in Atlanta? Don't miss the HAYA team's poster presentation on "Preclinical Evaluation of HTX-001 as a Novel Anti-fibrotic Therapy for Non-Obstructive HCM”, on Friday, September 27.🫀 ➡️hcmsociety.org/agenda